Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How would you tailor immunosuppression in an elderly patient presenting with primary FSGS?
Answer from: at Community Practice
Would use less [or avoid] high dose glucocorticoids. Rituximab would be preferred approach. Other options include CNIs and MMF.
Sign in or Register to read more
28416
Related Questions
Do you prefer starting a SGLT2i before steroids in patients with IgA nephropathy and proteinuria > 1.0 gram/day who are unable to tolerate ACEi/ARB due to hypotension?
Do you modify the albumin level below which you would prophylactically anticoagulate a pregnant patient with nephrotic-range proteinuria, given that hypoalbuminemia is expected in pregnancy?
What steroid regimen do you typically use for induction therapy in patients with lupus nephritis?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
Do you routinely obtain serum anti-THSD7A and anti-NELL1 tests in your patients with nephrotic syndrome suspected secondary to membraneous nephropathy?
Do you assess for podocyte detachment in addition to effacement when considering the degree of glomerular injury and potential treatment options following a native kidney biopsy in a patient with proteinuria?
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
How do you manage oral prednisone when initiating nefecon in a patient with IgA nephropathy?
What are your top takeaways from ASN 2024?